-
squamous cell carcinoma has reached the primary endpoint and intends to submit a marketing application for ® a new indication
Time of Update: 2023-02-03
On January 3, 2023, CStone Pharmaceuticals (02616. HK) reported that its potentially best-in-class PD-L1 antibody Zogeminec (sugemelimab ® injection) first-line clinical study for esophageal squamous
-
the primary endpoint and intends to submit a marketing application for a new indication
Time of Update: 2023-02-02
CStone Pharmaceuticals (HKEx: 2616), a leading biopharmaceutical company focused on the development, development and commercialization of innovative immunotherapies and precision therapies for oncolo
-
Shaanxi Food Association submitted a new answer sheet
Time of Update: 2023-02-01
(Wang Jingchen) Preliminary review: Li Song Responsible editor: Zhao Yu Review: Wang Jinchen Yin Hu farewell to the old year, the rabbit makes a new year.
(Wang Jingchen) Preliminary review: Li Song Responsible editor: Zhao Yu Review: Wang Jinchen Yin Hu farewell to the old year, the rabbit makes a new year.
-
Junshi Biologics announced that it has submitted a marketing authorization application
Time of Update: 2023-01-05
Dr. Patricia Keegan, Chief Medical Officer of Junshi Biologics, said, "This month, we submitted our marketing applications for teripulimab to two major European regulatory agencies, which reflects the company's strong determination and efficient execution to promote innovative drugs for the benefit of patients around the world.
-
Teripulimab submits UK marketing application Junshi Biologics enters Europe and takes the next city
Time of Update: 2023-01-05
Dr. Patricia Keegan, Chief Medical Officer of Junshi Biologics, said, "This month, we submitted our marketing applications for teripulimab to two major European regulatory agencies, which reflects the company's strong determination and efficient execution to promote innovative drugs for the benefit of patients around the world.
-
Derizhi: The first AI-aided design drug officially submitted an IND application to the FDA
Time of Update: 2023-01-05
On November 21, 2022, MindRank has formally submitted its self-developed potential "Best" to the US Food and Drug Administration (FDA) after completing its pre-IND communication meeting with the FDA in Class "Application for a new drug (IND) for type 2 diabetes mellitus and weight loss indication for non-competitive oral glucagon-like peptide 1 (GLP-1) receptor small molecule agonist MDR-001 was accepted.
-
Teripulimab submits UK marketing application Junshi Biologics enters Europe and takes the next city
Time of Update: 2023-01-04
js?cdnversion='+~(-new Date()/36e5)]; This is the second marketing application for teripulimab in Europe, and its global commercialization is progressing steadily On November 24, 2022, Beijing time, Junshi Biologics (1877.
-
The two Singaporean companies submitted plans for the third submarine cable in Bangladesh
Time of Update: 2023-01-02
SingTel's proposal is to build a SEA-ME-WE6 submarine cable system connecting Southeast Asia, the Middle East and Europe, from Singapore to France, with a bandwidth of 5 terabits per second (TBPS) for a total investment of $72 million.
-
endpoint, and the regulatory application is about to be submitted
Time of Update: 2023-01-01
▎WuXi AppTec content team editorNovartis today announced positive results in its Phase 3 trial of its targeted radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitors (ARPIs).
-
The internationalization of this domestic pharmaceutical company "accelerated", and new drugs submitted marketing applications in Europe!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Recently, Hansen Pharmaceutical announced that the European Medicines Agency (EMA) has officially accepted the marketing application of ametinib mesylate tablets submitted by the company's partner EQRx for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, and for the treatment of locally advanced or metastatic NSCLC adult patients with EGFR T790M mutation-positive.
-
European Union: Allows dietary supplements made in South Korea not to submit ethylene oxide test reports
Time of Update: 2022-12-29
Table 1 Limits for ethylene oxide and 2-chloroethanol in each country or region On December 7, 2022, the Ministry of Food and Drug of South Korea announced that after several consultations with the EU, the two sides finally reached an agreement, and the EU agreed to delete the "Korean dietary supplements" products from the product catalog with strengthened control.
-
Final demand case submitted for the submarine cable project in the Western Islands of Scotland
Time of Update: 2022-12-28
Final demand case submitted for the submarine cable project in the Western Islands of ScotlandThe submarine cable will provide around 600 megawatts of new capacity and could be laid by 2023 if approved by Ofgem (UK electricity and gas office).
-
Eni submitted the Rovuma LNG project plan to the Momo government
Time of Update: 2022-11-26
Eni said the company discovered gas resources in the region about seven years ago, and the plan provides specific details for designing and building two gas lines that will eventually produce 7.
-
The Revision Plan of Fuzhou Urban Master Plan (2011-2020) was submitted for deliberation
Time of Update: 2022-11-21
Urban master planningAccording to reports, the "Fuzhou Urban Master Plan (2011-2020)" (hereinafter referred to as the "Fuzhou General Plan") was officially approved by the State Council in July 2015; In August 2015, Fuzhou New District was approved.
-
in the adult primary immunization phase II trial, and is submitting a Phase III clinical trial
Time of Update: 2022-11-15
The geometric mean titer (GMT) ratio of neutralizing antibodies observed two weeks after the second intramuscular injection of PTX-COVID19-B was statistically non-inferior in terms of Comirnaty®, an FDA-approved mRNA vaccine (jointly developed by Pfizer and BioNTech).
